Equities

Zhejiang Jiuzhou Pharmaceutical Co Ltd

603456:SHH

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)15.22
  • Today's Change-0.24 / -1.55%
  • Shares traded10.99m
  • 1 Year change-51.25%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based company mainly engaged in the production, sales and service of chemical raw materials and intermediates. The Company is committed to providing one-stop customized pharmaceutical contract development and manufacturing organization (CDMO) services to global pharmaceutical companies, biotechnology companies, scientific research institutions, and others, including small molecule chemical drugs, peptide drugs, conjugated drugs and small nucleic acid drugs. The CDMO projects served by the Company involve therapeutic areas such as anti-tumor, anti-heart failure, anti-depression, treatment of Parkinson's disease, anti-lung cancer, anti-virus, anti-diabetes, and anti-respiratory system infection.

  • Revenue in CNY (TTM)5.25bn
  • Net income in CNY989.32m
  • Incorporated1998
  • Employees4.88k
  • Location
    Zhejiang Jiuzhou Pharmaceutical Co LtdNo.99, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
  • Phone+86 57 688706789
  • Fax+86 57 688706788
  • Websitehttp://www.jiuzhoupharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.18bn208.25m12.40bn1.55k59.565.51--10.500.97690.97695.5410.550.37431.214.71764,598.406.695.869.157.5963.1555.4117.8717.201.0833.770.335627.5958.6932.2426.2029.9927.32--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.43bn523.43m13.13bn8.41k25.291.84--2.040.2020.2022.492.780.55682.394.60764,058.905.026.777.2510.5054.3663.249.0211.101.5340.710.145942.3212.20-0.826765.20-6.21-11.645.92
Mabwell Shanghai Bioscience Co Ltd191.35m-1.02bn13.15bn1.49k--5.46--68.73-2.55-2.550.47896.020.04120.047216.79128,337.60-22.02-37.61-26.37-45.9596.8481.54-534.78-2,112.261.96--0.442--361.0327.88-10.28--17.35--
Zhejiang Jiuzhou Pharmaceutical Co Ltd5.25bn989.32m13.91bn4.88k14.021.60--2.651.101.105.849.690.45231.874.361,076,055.008.5210.1011.0713.6935.8034.6418.8316.262.07--0.181640.791.4424.2912.2045.7432.1420.11
Henan Lingrui Pharmaceutical Co., Ltd.3.43bn614.24m13.95bn2.53k22.574.72--4.071.091.096.095.210.72462.0413.841,356,471.0012.9710.6821.2716.5671.7474.4217.9014.921.26--0.012272.8010.3110.0322.0918.49-16.4739.77
Sunshine Guojian Pharmcutcl Shngh Co Ltd1.07bn352.22m14.25bn965.0040.472.86--13.280.5710.5711.748.090.20781.149.251,112,527.006.611.326.931.4177.8580.7431.816.556.66--0.018.2522.84-2.35497.63-4.4421.22--
Suzhou Zelgen Biopharmaceuticals Co Ltd386.57m-260.85m14.50bn867.00--9.10--37.50-1.00-1.001.496.020.16210.25943.75445,874.00-11.74-27.13-20.82-39.2092.2992.75-72.40-220.712.15--0.3842--27.83211.8139.08--41.38--
Changchun BCHT Biotechnology Co1.92bn543.19m15.06bn1.24k27.673.68--7.861.321.324.649.880.41160.84591.551,543,550.0011.679.9514.1412.8189.9086.6328.3624.032.03--0.015810.5570.3012.36175.9831.3721.04--
Shanghai Shyndec Pharmaceutical Co Ltd11.78bn843.91m15.29bn11.61k17.831.20--1.300.63940.63948.959.480.60693.086.611,014,487.005.754.858.508.1737.0943.009.487.031.82--0.105717.52-6.861.2910.21-0.3897-2.210.00
Liaoning Cheng Da Co Ltd11.18bn17.48m15.50bn3.36k779.230.5313--1.390.0130.0137.3419.070.23584.416.493,330,121.00-0.53663.59-0.76445.2116.0314.15-2.289.890.7792--0.283415.93-25.97-10.97-80.95-21.267.04--
Data as of May 24 2024. Currency figures normalised to Zhejiang Jiuzhou Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

21.83%Per cent of shares held by top holders
HolderShares% Held
Zhong Ou Asset Management Co., Ltdas of 30 Sep 202363.81m7.68%
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 202332.46m3.91%
GF Fund Management Co., Ltd.as of 31 Dec 202315.54m1.87%
Hwabao WP Fund Management Co., Ltd.as of 30 Sep 202313.95m1.68%
China Universal Asset Management Co., Ltd.as of 31 Dec 202313.45m1.62%
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 31 Dec 202311.31m1.36%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 20239.22m1.11%
Yinhua Fund Management Co., Ltd.as of 31 Dec 20238.57m1.03%
China Merchants Fund Management Co., Ltd.as of 31 Dec 20236.84m0.82%
Harvest Fund Management Co., Ltd.as of 31 Dec 20236.27m0.76%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.